JP2005247873A5 - - Google Patents

Download PDF

Info

Publication number
JP2005247873A5
JP2005247873A5 JP2005159852A JP2005159852A JP2005247873A5 JP 2005247873 A5 JP2005247873 A5 JP 2005247873A5 JP 2005159852 A JP2005159852 A JP 2005159852A JP 2005159852 A JP2005159852 A JP 2005159852A JP 2005247873 A5 JP2005247873 A5 JP 2005247873A5
Authority
JP
Japan
Prior art keywords
acid
hydroxy
diphosphonic acid
bisphosphonate
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005159852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005247873A (ja
JP5005188B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005247873A publication Critical patent/JP2005247873A/ja
Publication of JP2005247873A5 publication Critical patent/JP2005247873A5/ja
Application granted granted Critical
Publication of JP5005188B2 publication Critical patent/JP5005188B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2005159852A 2000-06-20 2005-05-31 ビホスホネートの投与法 Expired - Lifetime JP5005188B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US09/597,135 2000-06-20
US26768901P 2001-02-09 2001-02-09
US60/267,689 2001-02-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002503265A Division JP4722375B2 (ja) 2000-06-20 2001-06-18 ビホスホネートの投与法

Publications (3)

Publication Number Publication Date
JP2005247873A JP2005247873A (ja) 2005-09-15
JP2005247873A5 true JP2005247873A5 (https=) 2008-07-17
JP5005188B2 JP5005188B2 (ja) 2012-08-22

Family

ID=26952565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002503265A Expired - Lifetime JP4722375B2 (ja) 2000-06-20 2001-06-18 ビホスホネートの投与法
JP2005159852A Expired - Lifetime JP5005188B2 (ja) 2000-06-20 2005-05-31 ビホスホネートの投与法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002503265A Expired - Lifetime JP4722375B2 (ja) 2000-06-20 2001-06-18 ビホスホネートの投与法

Country Status (24)

Country Link
US (1) US8052987B2 (https=)
EP (1) EP1296689B3 (https=)
JP (2) JP4722375B2 (https=)
KR (1) KR100864743B1 (https=)
CN (1) CN1272013C (https=)
AT (1) ATE304856T1 (https=)
AU (2) AU7410901A (https=)
BR (1) BR0111806A (https=)
CA (1) CA2410201C (https=)
CY (2) CY1113740T1 (https=)
CZ (1) CZ301972B6 (https=)
DE (1) DE60113537T3 (https=)
DK (1) DK1296689T3 (https=)
ES (2) ES2247123T7 (https=)
HU (1) HU228400B1 (https=)
IL (2) IL153229A0 (https=)
MX (1) MXPA02012682A (https=)
NO (1) NO330459B1 (https=)
NZ (1) NZ523086A (https=)
PL (1) PL203087B1 (https=)
PT (1) PT1591122E (https=)
SK (1) SK287278B6 (https=)
TW (1) TWI289451B (https=)
WO (1) WO2001097788A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
CA2497353C (en) * 2002-09-16 2012-08-28 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
TW200410701A (en) * 2002-10-15 2004-07-01 Novartis Ag Method of administering bisphosphonates
HRP20041013B1 (hr) 2002-12-20 2013-10-25 F. Hoffmann - La Roche Ag Formulacija visoke doze ibandronata
US20070191311A1 (en) * 2004-01-30 2007-08-16 Shuichiro Kakimoto P2x receptor inhibitor
EP1930011B1 (en) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
WO2006062876A2 (en) * 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007124274A1 (en) * 2006-04-21 2007-11-01 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
US20210369769A1 (en) * 2018-11-02 2021-12-02 Dyve Biosciences, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0381296B1 (en) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3776880D1 (de) 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
RU2112515C1 (ru) 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
EP0648120B1 (en) 1992-06-30 1997-12-29 PROCTER & GAMBLE PHARMACEUTICALS, INC. Use of phosphonates for the treatment of osteoporosis
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
EP0779812A4 (en) 1994-09-09 1997-09-10 Procter & Gamble Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
JPH10505091A (ja) 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
ES2239774T3 (es) 1995-09-29 2005-10-01 Novartis Ag Metodo de tratamiento de la enfermedad navicular en caballos.
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
TR200000145T2 (tr) 1997-07-22 2000-05-22 Merck & Co. Inc. Kemik erimesini durdurmak için bir yöntem
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover

Similar Documents

Publication Publication Date Title
JP2005247873A5 (https=)
CA2410201A1 (en) Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
JP2006506365A5 (https=)
RU2003133773A (ru) Фармацевтическое применение бисфосфонатов
JP2004528340A5 (https=)
RU2003117702A (ru) Применение бисфосфонатов для лечения боли
US20070161603A1 (en) Method of administering bisphosphonates
JP2002529490A5 (https=)
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
JP2003500352A5 (https=)
AU775079B2 (en) Pharmaceutical compositions and uses
RU2002121643A (ru) Фармацевтическая парентеральная композиция, содержащая бифосфонат
JP2006500401A5 (https=)
JP2009522369A5 (https=)
RU2003100503A (ru) Способ введения бисфосфонатов
RU2001133352A (ru) Применение бисфосфоновых кислот для лечения ангиогенеза
EP1591122A1 (en) Method of administering bisphosphonates
HK1068550A (en) Use of bisphosphonates for pain treatment